New strategies for active immunotherapy with genetically engineered tumor cells
- 31 December 1992
- journal article
- review article
- Published by Elsevier in Current Opinion in Immunology
- Vol. 4 (5) , 619-623
- https://doi.org/10.1016/0952-7915(92)90037-f
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability.The Journal of Experimental Medicine, 1992
- CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clonesNature, 1992
- A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human MelanomaScience, 1991
- Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4Science, 1991
- Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation.The Journal of Experimental Medicine, 1991
- Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity.The Journal of Experimental Medicine, 1990
- Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor responseCell, 1990
- Structure of the gene of tum− transplantation antigen P91A: The mutated exon encodes a peptide recognized with Ld by cytolytic T cellsCell, 1989
- Murine interleukin-4 displays potent anti-tumor activity in vivoCell, 1989
- VIRAL ONCOLYSIS: INCREASED IMMUNOGENICITY OF HOST CELL ANTIGEN ASSOCIATED WITH INFLUENZA VIRUSThe Journal of Experimental Medicine, 1967